Discovery of potent selective orally active benzoxazepine-based orexin-2 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 21, 2011, Pages 6414-6416

  Fujimoto, Tatsuhiko ^a   Kunitomo, Jun ^a   Tomata, Yoshihide ^a   Marui, Shogo ^a   Nishiyama, Keiji ^a   Nakashima, Masato ^a   Yoshikubo, Shin Ichi ^a   Hirai, Keisuke ^a   Hirozane, Mariko ^b  

^a Takeda Pharmaceutical Company   (Japan)

^b Discovery Researcch Laboratories   (Japan)

Author keywords

Insomnia; Orexin 2 receptor antagonists; Sleep disorder

Indexed keywords

DIBENZOXAZEPINE DERIVATIVE; OREXIN 2 RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

RATTUS;

EID: 80054788101     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.08.093     Document Type: Article

References (25)

1. Sakurai, T.; Amemiya, A.; Ishii, M.; Matsuzaki, I.; Chemelli, R. M.; Tanaka, H.; Williams, S. C.; Richardson, J. A.; Kozlowski, G. P.; Wilson, S.; Arch, J. R.; Buckingham, R. E.; Haynes, A. C.; Carr, S. A.; Annan, R. S.; McNulty, D. E.; Liu, W. S.; Terrett, J. A.; Elshourbagy, N. A.; Bergsma, D. J.; Yanagisawa, M. Cell 1998, 92, 573.
2. (a) Lee, M. G.; Hassani, O. K.; Jones, B. E. J. Neurosci. 2005, 25, 6716;
3. (b) Estabrooke, I. V.; McCarthy, M. T.; Ko, E.; Chou, T. C.; Chemelli, R. M.; Yanagisawa, M.; Saper, C. B.; Scammell, T. E. J. Neurosci. 2001, 21, 1656.
4. (a) Coleman, P. J.; Renger, J. J. Expert Opin. Ther. Patents 2010, 20, 307. and references cited therein;
5. (b) Gatfield, J.; Brisbare-Roch, C.; Jenck, F.; Boss, C. ChemMedChem 2010, 5, 1197;
6. (c) Brisbare-Roch, C.; Dingemanse, J.; Koberstein, R.; Hoever, P.; Aissaoui, H.; Flores, S.; Mueller, C.; Nayler, O.; van Gerven, J.; de Haas, S. L.; Hess, P.; Qiu, C.; Buchmann, S.; Schertz, M.; Weller, T.; Fischli, W.; Clozel, M.; Jenck, F. Nat. Med. 2007, 13, 150;
7. (d) Coleman, P. J.; Cox, C. D.; Breslin, M. J.; Schreier, J. D.; Roecker, A. J.; Whitman, D. B.; Mercer, S. P.; Bergman, J. P.; Brashear, K. M.; McGaughey, G. G.; Bednar, R. A.; Lemaire, W.; Doran, S. M.; Fox, S. V.; Garson, S. L.; Harrell, C. M.; Kraus, R. L.; Murphy, K.; Reiss, D. R.; Cui, D.; Li, C.; Prueksaritanont, T.; Roller, S.; Tang, C.; Stevens, J.; Tannenbaum, P.; Young, S. D.; Koblan, K. S.; Hartman, G. D.; Renger, J. J. (MEDI-37) 239th ACS National Meeting & Exposition March 21-25, San Francisco, California 2010.;
8. (e) Cox, C. D.; Breslin, M. J.; Whitman, D. B.; Schreier, J. D.; McGaughey, G. B.; Bogusky, M. J.; Roecker, A. J.; Mercer, S. P.; Bednar, R. A.;Lemaire, W.; Bruno, J. G.; Reiss, D. R.; Harrell, C. M.; Murphy, K. L.; Garson, S. L.; Doran, S. M.; Prueksaritanont, T.; Anderson, W. B.; Tang, C.; Roller, S.; Cabalu, T. D.; Cui, D.; Hartman, G. D.; Young, S. D.; Koblan, K. S.; Winrow, C. J.; Renger, J. J.; Coleman, P. J. J. Med. Chem. 2010, 53, 5320
9. (f) Winrow, C. J.; Gotter, A. L.; Cox, C. D.; Doran, S. M.; Tannernbaum, P. L.; Breslin, M. J.; Garson, S. L.; Fox, S. V.; Harrell, C. M.; Stevens, J.; Reiss, D. R.; Cui, D.; Coleman, P. J.; Renger, J. . J. J. Neurogenet. 2011, 25, 52.
10. One of examples for quinoid bioactivation is troglitazone as PPAR gamma agonist. See references
11. (a) Blagg, J. Ann. Rep. Med. Chem. 2006, 41, 353;
12. (b) Kassahun, K.; Pearson, P. G.; Tang, W.; McIntosh, I.; Leung, K.; Elmore, C.; Dean, D.; Wang, R.; Doss, G.; Baillie, T. A. Chem. Res. Toxicol. 2001, 14, 62.
13. Kumar, S.; Kassahun, K.; Tschirret-Guth, R. A.; Mitra, K.; Baillie, T. A. Curr. Opin. Drug Discovery Des. 2008, 11, 43.
14. (a) Hansch, C.; Leo, A.; Unger, S. H.; Kim, K. H.; Nikaitani, D.; Lien, E. J. J. Med.Chem. 1973, 16, 1207
15. (b) Ojha, P. K.; Roy, K. Eur. J. Med. Chem. 2010, 45, 4645. and references cited therein..
16. Craig, P. N. Guidlines for drug and analogue design. In The Basis of Medicinal Chemistry, vol. 1; Wolff, M. E., Ed.; Wiley-Interscience: New York, 1980. p. 165.
17. The Japanese Pharmacopoeia Fourteenth Edition.
18. (a) Mensch, J.; Oyarzabal, J.; Mackie, C.; Augustijins, P. J. Pharm. Sci. 2009, 98, 4429
19. (b) Di, L.; Kerns, E. H.; Carter, G. T. Expert Opin. Drug Discov. 2008, 3, 677;
20. (c) Clark, D. E. Ann. Rep. Med. Chem. 2005, 40, 403.
21. Passive permeability as over 20 nm/s means high permeability. MDR1 directional transport ratio (B to A/A to B) as below 3.0 means low susceptibility of P-gp.
22. (a) Kunz, I. D.; Chen, K.; Sharp, K. A. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997;
23. (b) Hopkins, A. L.; Groom, C. R. Alex, Drug Discov. Today 2004, 9, 430;
24. (c) Abad-Zapatero, C. Expert Opin. Drug Discov. 2007, 2, 469. Ligand efficiency (LE) is the binding energy per heavy atom (kcal mol-1) = D G/number of heavy atoms =-1.36 log (OX2R IC50)/number of heavy atoms.
25. Bergman, J. M.; Roecker, A. J.; Mercer, S. P.; Bednar, R. A.; Reiss, D. R.; Ransom, R. W.; Harrell, C. M.; Pettibone, D. J.; Lemaire, W.; Murphy, K. L.; Li, C.; Preuksaritanont, T.; Winrow, C. J.; Renger, J. J.; Koblan, K. S.; Hartman, G. D.; Coleman, P. J. Bioorg. Med. Chem. Lett. 2008, 18, 1425.